Non Invasive PGT-A Launched Clinically In USA
LOS ANGELES, April 10, 2019 /PRNewswire/ -- Yikon Genomics and Viazoi, a genetic testing and wellness division of Foundation Laboratory, have collaborated to launch clinical Non Invasive PGT-A services in the USA, promising to revolutionize the fertility industry by enabling physicians to virtually eliminate false negatives due to mosaicism, and giving these physicians and patients peace of mind in their embryo screening processes. Noninvasive PGT-A allows embryos to be screened for chromosomal aneuploidy prior to implantation without the previously utilized invasive methodology of a biopsy. Instead, the culture medium used during in-vitro embryo culture is collected and then processed for aneuploidy screening, through library preparation and NGS (next generation sequencing). This innovative technique enables PGT-A to be performed in an easier, safer, more accurate, and more cost-effective way.
Viazoi has validated Yikon's Non Invasive PGT-A and, together with Yikon Genomics, is commercially offering this service to the USA Fertility market.
"We are honored to partner with Viazoi, in order to introduce Yikon's PGT-A solutions in to the USA. Viazoi and Yikon have similar visions of impacting and changing patients' lives, and we greatly look forward to accomplishing this them," expresses Sijia Lu, CEO of Yikon Genomics.
"It was a very obvious decision to partner with Yikon and offer our NextGen sequencing production capacity to support Yikon's non-invasive PGS testing as there is valuable genetic information at the embryonic level that parents can review and make very important decisions with," states Zareh Baghoomian, VP of Operations at Viazoi.
"We are very pleased about our relationship with Yikon and the opportunity to provide our decades of testing experience to Yikon. It's very exciting to support a premiere PGS company such as Yikon in their efforts to revolutionize IVF related clinical testing. For Viazoi, this is a wonderful opportunity to expand our service capabilities worldwide," expresses Areg Boyamyan, Senior Vice President of Viazoi and Foundation Laboratory.
"We have worked diligently to identify strategic partners in the USA, in order to introduce Yikon's groundbreaking technologies to the IVF market. We are honored to be able to partner with Viazoi and Foundation Laboratory to accomplish this goal, and look forward to impacting the lives of patients across the country," quotes Brandon Hensinger, Vice President of Sales of Yikon Genomics.
Yikon Genomics is a leading solution-based single cell sequencing company based in Shanghai China, with global operations out of the USA, providing complete solutions in the fields of reproductive health and cancer diagnostics. Yikon's ChromInst and NICSInst PGT-A solutions provide the most accurate and comprehensive embryo screening results, to allow physicians to choose healthy embryos for their patients. Yikon's PGT solutions have enabled thousands of couples to achieve healthy pregnancies.
As a leader in diagnostic testing, Foundation Laboratory is a CLIA certified diagnostic testing laboratory that has been in business for over 60 years. With the desire to offer more than just clinical testing, Foundation Laboratory formed a new division called Viazoi, whose meaning in Latin and Greek is "Through Life". Viazoi offers genetic testing insights into multiple areas of wellness, interpreting individuals' genetic information to create wellness programs that translate individuals' genotyping data into actionable results that can have a real impact on a person's life and daily choices to support their wellness journey.
For more information about utilizing Non Invasive PGT-A, or media inquiries, please contact Brandon Hensinger, Vice President of Sales of Yikon Genomics, at brandon@yikongenomics.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/non-invasive-pgt-a-launched-clinically-in-usa-300830134.html
SOURCE Yikon Genomics
